Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Investigating the Mutant Estrogen Receptor and its Implications in Mammary Tumorigenesis
EF 2018-19
Résumé
An estimated one in eight women will be diagnosed with breast cancer in her lifetime. Resistance to traditional treatments is a major contributor to recurrence of the disease and relapse in patients who previously responded well to therapy.
A protein called the “estrogen receptor” is expressed in about 75% of breast cancer diagnoses. This protein is activated by the estrogen hormone, which is produced naturally in the human body. When activated, the estrogen receptor causes the cancer cells to divide more rapidly than usual, producing a tumour. This kind of breast cancer is traditionally treated with hormone therapy, but patients frequently develop resistance to the drugs and their cancer comes back. We are investigating the mechanisms behind this resistance and how other proteins can act with the estrogen receptor to promote cancer progression.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
415343
Name
Moore Michaela J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Mutant Estrogen Receptor and its Implications in Mammary Tumorigenesis
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Estrogen Receptor; Mammary Gland Development; Metastasis; Mouse Models; Nf1; Pi3k
Abstract
An estimated one in eight women will be diagnosed with breast cancer in her lifetime. Resistance to traditional treatments is a major contributor to recurrence of the disease and relapse in patients who previously responded well to therapy.
A protein called the “estrogen receptor” is expressed in about 75% of breast cancer diagnoses. This protein is activated by the estrogen hormone, which is produced naturally in the human body. When activated, the estrogen receptor causes the cancer cells to divide more rapidly than usual, producing a tumour. This kind of breast cancer is traditionally treated with hormone therapy, but patients frequently develop resistance to the drugs and their cancer comes back. We are investigating the mechanisms behind this resistance and how other proteins can act with the estrogen receptor to promote cancer progression.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Moore, Michaela J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~